ESMO 2014 Highlights

CLEOPATRA: Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab

Phoebe Starr

October 2014, Vol 5 , No 8 - ESMO 2014 Highlights

Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. This should become the new standard of care for patients with metastatic HER2 disease, according to the study investigators, who presented their results at the 2014 European Society for Medical Oncology (ESMO) Congress. [ Read More ]

Mixed Results with Postprogression EGFR Inhibition in Advanced Non–Small-Cell Lung Cancer

Charles Bankhead

October 2014, Vol 5 , No 8 - ESMO 2014 Highlights

Madrid, Spain—Continuing an EGFR inhibitor after acquired resistance does not slow the progression of advanced non–small-cell lung cancer (NSCLC) in patients receiving chemotherapy, according to a report presented at the 2014 European Society for Medical Oncology (ESMO) Congress. However, extending anti-EGFR therapy with erlotinib beyond disease progression may be beneficial, according to a second report presented at the meeting. [ Read More ]

PD-1–Blocking Nivolumab Shows Impressive Responses in Melanoma

Phoebe Starr

October 2014, Vol 5 , No 8 - ESMO 2014 Highlights

Madrid, Spain—Immunotherapy marches on, showing continued progress in treating advanced melanoma. At the 2014 European Society for Medical Oncology (ESMO) Congress, first reports from a phase 3 clinical trial showed that the monoclonal anti–PD-1 antibody nivolumab achieved superior responses and longer progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in the second- or third-line treatment of patients whose melanoma progressed with ipilimumab therapy. [ Read More ]

Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab – Dual HER2 blockade a new standard of care

Phoebe Starr

October 2014, Vol 5 , No 8 - ESMO 2014 Highlights

Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with HER2-positive metastatic breast cancer. [ Read More ]